A high-level overview of Stoke Therapeutics, Inc. (STOK) stock. View (STOK) real-time stock price, chart, news, analysis, analyst reviews and more.

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from Stoke Therapeutics in a deal that included an upfront payment of $165 ...

After the FDA rejection of Zurzuvae in one type of depression and the triple failure of neuro asset dalzanemdor, Sage was ...

Inhibiting an overabundant enzyme saved a key component of a brain signaling pathway that is vital for motor control in a ...

Biogen acquired rights to Skyclarys in 2023 when it bought Reata Pharma for $7.3 billion. Analysts have previously suggested that the drug could make sales of more than $1 billion a year at its peak.

Find the latest Savara Inc. (SVRA) stock quote, history, news and other vital information to help you with your stock trading and investing.